First in our summer Research Round Up podcast series, Charles Loprinzi, MD, and Ezra Cohen, MD, unpack some of science highlights from the 2015 ASCO Annual Meeting.
In January, Randy Hillard was part of the U.S. Food and Drug Administration committee that considered the first application for a “biosimilar” medication. In this guest post, he describes patients’ role in the drug approval process and how the committee’s decision could influence cancer care in the future.
In this podcast, experts Charles Ryan, MD, and Thomas Powles, MD, talk about bladder cancer treatment, including some of the new approaches that are being developed.
Two out of three people now live at least five years after being diagnosed with cancer, but there is still more to be done. Researchers at the 2015 ASCO Annual Meeting showed how new treatment options can continue to improve and lengthen the lives of people with both rare and common cancers.
Is More Extensive Surgery Better for Early-Stage Oral Cancer? – Research from the 2015 ASCO Annual Meeting
Doctors worldwide have struggled with this question for decades. A new study presented today at the 2015 ASCO Annual Meeting provides clarification on whether lymph nodes should be removed before or after cancer has been detected in the nodes of people with early-stage oral cancer.
This year, President Obama has focused attention on treatments and tools that help doctors tailor medical care for individual patients. Research presented at the 2015 ASCO Annual Meeting shows how targeted therapies can be used to improve the care of people with a number of different types of blood cancer.
Immunotherapy is one of the hottest topics in cancer research. This year, focus at the ASCO Annual Meeting has been on a type of immunotherapy called PD-1 inhibitors. Learn how these drugs may help improve the treatment of head and neck, liver, and lung cancers.
In this podcast, experts discuss ASCO’s recent endorsement of ASTRO’s guideline for radiation therapy for non-small cell lung cancer.
Dr. Julie Brahmer from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins shares details about the recent FDA approval of nivolumab (Opdivo) for advanced non-small cell lung cancer. She explains how this impacts the treatment of lung cancer.
People with cancer often take dietary and herbal products to boost health, improve nutrition, or reduce treatment side effects. However, these products are not approved by the U.S. Food and Drug Administration like drugs and may interact with standard cancer treatments.